Medtronic PLC (MDT) Holdings Reduced by Bp Plc

Share on StockTwits

Bp Plc lessened its position in Medtronic PLC (NYSE:MDT) by 14.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 144,000 shares of the medical technology company’s stock after selling 24,000 shares during the period. Bp Plc’s holdings in Medtronic were worth $13,100,000 as of its most recent filing with the SEC.

A number of other large investors have also recently modified their holdings of the business. First Midwest Bank Trust Division boosted its stake in shares of Medtronic by 22.9% in the third quarter. First Midwest Bank Trust Division now owns 6,500 shares of the medical technology company’s stock worth $639,000 after buying an additional 1,211 shares during the last quarter. Stillwater Capital Advisors LLC boosted its stake in shares of Medtronic by 0.9% in the third quarter. Stillwater Capital Advisors LLC now owns 124,225 shares of the medical technology company’s stock worth $12,220,000 after buying an additional 1,079 shares during the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH boosted its stake in shares of Medtronic by 6.8% in the third quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 92,208 shares of the medical technology company’s stock worth $8,961,000 after buying an additional 5,842 shares during the last quarter. Telemus Capital LLC boosted its stake in shares of Medtronic by 4.9% in the third quarter. Telemus Capital LLC now owns 11,590 shares of the medical technology company’s stock worth $1,140,000 after buying an additional 544 shares during the last quarter. Finally, Weatherstone Capital Management purchased a new stake in shares of Medtronic in the third quarter worth about $212,000. 81.03% of the stock is owned by hedge funds and other institutional investors.

In other news, CEO Omar Ishrak bought 12,000 shares of the firm’s stock in a transaction dated Wednesday, January 9th. The shares were acquired at an average price of $84.05 per share, for a total transaction of $1,008,600.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Karen L. Parkhill bought 3,000 shares of the firm’s stock in a transaction dated Wednesday, January 9th. The stock was purchased at an average price of $83.87 per share, for a total transaction of $251,610.00. The disclosure for this purchase can be found here. Company insiders own 0.28% of the company’s stock.

NYSE MDT opened at $92.80 on Thursday. The company has a market capitalization of $124.00 billion, a PE ratio of 19.45, a PEG ratio of 2.45 and a beta of 0.82. Medtronic PLC has a 1-year low of $76.41 and a 1-year high of $100.15. The company has a current ratio of 2.56, a quick ratio of 2.11 and a debt-to-equity ratio of 0.48.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, February 19th. The medical technology company reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.05. The business had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.53 billion. Medtronic had a return on equity of 13.51% and a net margin of 7.44%. The business’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.17 earnings per share. On average, research analysts predict that Medtronic PLC will post 5.12 earnings per share for the current fiscal year.

A number of equities analysts have issued reports on MDT shares. Zacks Investment Research downgraded Medtronic from a “buy” rating to a “hold” rating in a research report on Friday, November 16th. Oppenheimer reiterated a “buy” rating and set a $104.00 price target on shares of Medtronic in a research report on Tuesday, November 20th. Raymond James lowered their price target on Medtronic from $105.00 to $104.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 21st. UBS Group started coverage on Medtronic in a research report on Wednesday, November 28th. They set a “buy” rating and a $112.00 price target on the stock. Finally, Credit Suisse Group started coverage on Medtronic in a research report on Monday, December 17th. They set an “outperform” rating and a $109.00 price target on the stock. Nine investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $104.09.

TRADEMARK VIOLATION WARNING: “Medtronic PLC (MDT) Holdings Reduced by Bp Plc” was first published by Macon Daily and is the property of of Macon Daily. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://macondaily.com/2019/02/21/medtronic-plc-mdt-holdings-reduced-by-bp-plc.html.

Medtronic Profile

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.

Featured Article: Bear Market

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.